BioWorld

Oct. 12, 2010

View Archived Issues

Alexza Takes Tumble on FDA Rejection; No Surprise for Jazz

Read More

Biotech Foundations: Biotech VC Larry Bock Uses Start-up Spirit in Science Fest

Read More

Other News To Note

Read More

Stock Movers

Read More

Financings Roundup

Read More

ESMO Roundup

Read More

Clinic Roundup

Read More

Exelixis, BMS Ink More Deals Worth Total Potential $565M

Exelixis Inc. continued its cozy relationship with longtime partner Bristol-Myers Squibb Co., entering two more agreements worth a combined potential $565 million. (BioWorld Today) Read More

ImmunoGen Gets $45M Up Front from Novartis for TAP

Read More